Amgen (AMGN) Stock Forecast & Price Target

$263.38 +2.19 (+0.84%)

(As of 12/20/2024 05:40 PM ET)

Amgen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 25 Analyst Ratings

Sell
2

Hold
12

Buy
11

Based on 25 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 25 analysts, 2 have given a sell rating, 12 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$319.67
21.37% Upside

According to the 25 analysts' twelve-month price targets for Amgen, the average price target is $319.67. The highest price target for AMGN is $405.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted upside of 21.37% from the current price of $263.38.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

AMGN Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	13 Buy rating(s)
Hold	12 Hold rating(s)	13 Hold rating(s)	11 Hold rating(s)	6 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$319.67	$333.57	$327.28	$285.71
Forecasted Upside	21.37% Upside	15.12% Upside	-2.99% Downside	0.55% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	21.37% Upside	25,828.56% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent AMGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Underperform	$256.00	-7.79%
11/27/2024	Citigroup 3 of 5 stars	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$335.00 ➝ $310.00	+10.71%
11/27/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Lower Target		$305.00 ➝ $285.00	+1.78%
11/27/2024	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$200.00 ➝ $195.00	-30.36%
11/27/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$349.00 ➝ $302.00	+7.85%
11/27/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$360.00 ➝ $330.00	+17.85%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/12/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$380.00 ➝ $380.00	+28.07%
11/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$335.00 ➝ $326.00	+1.31%
10/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+28.41%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$381.00 ➝ $383.00	+20.14%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$380.00	+18.15%
10/14/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$320.00 ➝ $333.00	+1.42%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$300.00 ➝ $315.00	-0.48%
9/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform ➝ Underperform	$215.00 ➝ $215.00	-31.92%
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$320.00 ➝ $335.00	+1.84%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$310.00 ➝ $303.00	-6.67%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$223.00 ➝ $235.00	-23.53%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
3/28/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%
4/28/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$293.00 ➝ $288.00	+19.83%
2/2/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$282.00 ➝ $267.00	+8.36%
2/1/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$307.00 ➝ $289.00	+14.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:45 AM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen Inc. has received multiple upgrades from analysts, with a recent upgrade from StockNews.com raising its rating from "buy" to "strong-buy," indicating strong confidence in the company's future performance.
The stock is currently trading at approximately $274.06, which is significantly lower than its one-year high of $346.85, suggesting potential for price appreciation as it approaches previous highs.
Institutional investors own 76.50% of Amgen Inc.'s stock, reflecting strong confidence from large financial entities in the company's stability and growth prospects.
Amgen Inc. has a solid market capitalization of $147.32 billion, which provides a cushion against market volatility and indicates a well-established presence in the biotechnology sector.
Recent analyst reports have set an average price target of $319.68, suggesting that there is room for growth in the stock price, making it an attractive investment opportunity.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

Amgen Inc. has a high debt-to-equity ratio of 7.55, which indicates that the company relies heavily on debt financing. This could pose risks, especially in a rising interest rate environment.
Despite recent upgrades, two analysts have rated the stock with a "sell" rating, suggesting that there are concerns about its future performance that investors should consider.
The stock has experienced significant volatility, with a 50-day moving average of $303.87 compared to its current price, indicating that it may be overvalued at present levels.
Amgen Inc. has a P/E ratio of 35.21, which is relatively high compared to industry averages, suggesting that the stock may be overvalued and could face downward pressure if earnings do not meet expectations.
Recent trading volumes have fluctuated, with a notable drop in average volume, which may indicate reduced investor interest and could lead to increased volatility in the stock price.

AMGN Forecast - Frequently Asked Questions

: According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $319.67, with a high forecast of $405.00 and a low forecast of $195.00.
: 25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 12 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
: According to analysts, Amgen's stock has a predicted upside of 21.37% based on their 12-month stock forecasts.
: Over the previous 90 days, Amgen's stock had 1 upgrade and 1 downgrade by analysts.
: Amgen has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, Leerink Partners, Redburn Partners, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Amgen less than other "medical" companies. The consensus rating for Amgen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

What most folks don’t know about oil (BIG missed opportunity) (Ad)

$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.

And expects this underappreciated niche to continue rallying well into 2026.

This page (NASDAQ:AMGN) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Stock Forecast & Price Target